Microtest aseptic manufacturing expansion brings new contract

By Emilie Reymond

- Last updated on GMT

Related tags: Clinical trial

Microtest Labs has bagged a new contract with UK-based Antisoma to make clinical quantities of the firm's new cancer drug - just a few months after expanding its manufacturing capacity.

Under the terms of the agreement, Massachusetts-based contract manufacturer Microtest will be in charge of the formulation and aseptic fill/finish of Antisoma's AS1411 drug for forthcoming Phase II trials. In addition, the firm will conduct stability testing of the product. "This agreement provides a strategic opportunity for us at Microtest to form a strong working partnership with an important category leader like Antisoma,"​ said Steve Richter, Microtest's president. This latest contract comes just five months after Microtest completed the expansion of its contract parenteral manufacturing services with a $7.5m (€5.6m) investment at its Agawam, Massachusetts headquarters facilities. The investment has enabled the firm to substantially expand its aseptic processing capacity and double the size of its facilities. The expansion included constructing and equipping new pharmaceutical testing laboratory facilities, a series of segregated virology testing laboratories, and new aseptic fill/finish manufacturing facilities, along with the hiring of additional staff. Microtest's pharmaceutical and virology test services can support full in-process and product release testing as well as product stability testing, raw material qualification and assay development/validation. Richter claims that Microtest can deliver fill/finish services integrated with stability and testing services for a complete solution that lowers cost, improves quality, and compresses time to revenue. "The result is immediate project start-up, a single technology transfer, easier regulatory submissions, and accelerated time to clinical trials,"​ he said.

Related news

Related products

show more

A Winning End-to-End Solution for Oncology Studies

A Winning End-to-End Solution for Oncology Studies

Clinical Ink | 22-Feb-2021 | Technical / White Paper

Oncology clinical trials present a unique set of challenges for patients, study sites, and study sponsors. Using electronic patient reported outcomes (ePRO)...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Related suppliers

Follow us


View more